Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models

MLA

Marilin S Koch, et al. “Systemic High-Dose Dexamethasone Treatment May Modulate the Efficacy of Intratumoral Viral Oncolytic Immunotherapy in Glioblastoma Models.” Journal for Immunotherapy of Cancer, vol. 10, no. 1, Nov. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....82b8be09b80beec58beda1af9d511f57&authtype=sso&custid=ns315887.

APA

Marilin S Koch, Mykola Zdioruk, Michal O Nowicki, Alec M Griffith, Estuardo Aguilar, Laura K Aguilar, Brian W Guzik, Francesca Barone, Paul P Tak, Ghazaleh Tabatabai, James A Lederer, E Antonio Chiocca, & Sean Lawler. (2021). Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models. Journal for Immunotherapy of Cancer, 10(1).

Chicago

Marilin S Koch, Mykola Zdioruk, Michal O Nowicki, Alec M Griffith, Estuardo Aguilar, Laura K Aguilar, Brian W Guzik, et al. 2021. “Systemic High-Dose Dexamethasone Treatment May Modulate the Efficacy of Intratumoral Viral Oncolytic Immunotherapy in Glioblastoma Models.” Journal for Immunotherapy of Cancer 10 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....82b8be09b80beec58beda1af9d511f57&authtype=sso&custid=ns315887.